Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 14633703 
Xu W, et al. (2003) The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer Res 63, 7777-84 14633703
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  SKBr3 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
PHOSPHATASE PPP1CA (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PPP1CA (human) co-immunoprecipitation, transfection of constitutively active enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
geldanamycin decrease
heregulin increase
geldanamycin no effect upon treatment-induced increase
LY294002 no effect upon treatment-induced increase
geldanamycin decrease
calyculin A increase
geldanamycin calyculin A no effect upon treatment-induced increase
microcystin-LR increase
tautomycin increase
geldanamycin tautomycin no effect upon treatment-induced increase
geldanamycin inhibit treatment-induced increase inhibition at lower concentations of okadaic acid
bpV increase
geldanamycin no effect upon treatment-induced increase
ZD1839 decrease
ZD1839 bpV no effect upon treatment-induced increase
heregulin ZD1839 inhibit treatment-induced decrease
okadaic acid increase
ZD1839 okadaic acid no effect upon treatment-induced increase

S21-p - GSK3A (human)
Orthologous residues
GSK3A (human): S21‑p, GSK3A (mouse): S21‑p, GSK3A (rat): S21‑p, GSK3A (cow): S21‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  SKBr3 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
geldanamycin decrease
ZD1839 decrease

S9-p - GSK3B (human)
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S3‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  SKBr3 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
geldanamycin decrease
ZD1839 decrease

Y1248-p - HER2 (human)
Orthologous residues
HER2 (human): Y1248‑p, HER2 iso2 (human): Y638‑p, HER2 (mouse): Y1249‑p, HER2 (rat): Y1250‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  SKBr3 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
geldanamycin decrease
geldanamycin decrease
bpV increase
geldanamycin inhibit treatment-induced increase
ZD1839 decrease
ZD1839 bpV inhibit treatment-induced increase
ZD1839 bpV no effect upon treatment-induced increase

T320-p - PPP1CA (human)
Orthologous residues
PPP1CA (human): T320‑p, PPP1CA (mouse): T320‑p, PPP1CA (rat): T320‑p, PPP1CA (rabbit): T320‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  SKBr3 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE Akt1 (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PPP1CA (human) no change compared to control
Akt1 (human) no change compared to control
Akt1 (human), PPP1CA (human) increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.